Juno-Novartis CAR-T Settlement Puts Focus Back In Clinic
This article was originally published in The Pink Sheet Daily
Novartis agrees to pay Juno an initial $12.25 million, plus future milestone payments and royalties to resolve patent and contract dispute; Juno to share payments with St. Jude.
You may also be interested in...
Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Cancer immunotherapy's potential payoff is big enough that acknowledged competitors are settling disputes, potential competitors are forging alliances, and start-ups like their chances of success. Profiles of Annias Immunotherapeutics, Costanoan Immunotherapies, and Unum Therapeutics.